Naomasa Asaka

Cardioprotective profile of MET‐88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts

Naomasa Asaka, Yoshinori Muranaka, Tsukasa Kirimoto et al. · Fundamental and Clinical Pharmacology · 1998 · 31 citations

Effects of MET-88, a .GAMMA.-Butyrobetaine Hydroxylase Inhibitor, on Tissue Carnitine and Lipid Levels in Rats.

Yukio Hayashi, Tsukasa Kirimoto, Naomasa Asaka et al. · Biological and Pharmaceutical Bulletin · 2000 · 29 citations · Full text

.Gamma.-butyrobetaine Hydroxylase Inhibitor, Lipid Peroxidation, Pharmacotherapy +17

Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction

Yukio Hayashi, Tsukasa Kirimoto, Naomasa Asaka et al. · European Journal of Pharmacology · 2000 · 28 citations

Cardiomyopathy, Heart Failure, Cardiovascular Disease +11

Synthesis and aldose reductase inhibitory activity of acetic acid derivatives of pyrrolo[1,2-c]imidazole

Ichiro Yamawaki, Yasuhiko Matsushita, Naomasa Asaka et al. · European Journal of Medicinal Chemistry · 1993 · 21 citations

Medicinal Chemistry, Biosynthesis, Bioorganic Chemistry +9

Beneficial effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts.

Tsukasa Kirimoto, Kiyoshi Nobori, Naomasa Asaka et al. · PubMed · 1997 · 19 citations

Cardiovascular Pharmacology, Gamma-butyrobetaine Hydroxylase Inhibitor, Pharmacotherapy +20